Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
The latest update is out from Accuray ( (ARAY) ).
Accuray reported its financial results for the fourth quarter and fiscal year 2025, noting a 5% decrease in quarterly net revenue to $127.5 million and a 3% increase in annual net revenue to $458.5 million. Despite macroeconomic challenges, the company achieved a net income of $1.1 million for the quarter and a reduced net loss of $1.6 million for the year, alongside completing a debt refinancing. Accuray’s fiscal 2026 guidance anticipates net revenue between $471 million and $485 million, reflecting its strategic focus on innovation and service growth.
The most recent analyst rating on (ARAY) stock is a Buy with a $6.00 price target. To see the full list of analyst forecasts on Accuray stock, see the ARAY Stock Forecast page.
Spark’s Take on ARAY Stock
According to Spark, TipRanks’ AI Analyst, ARAY is a Neutral.
Accuray presents a mixed investment opportunity. While recent earnings and corporate actions demonstrate potential for growth, the stock’s high valuation, leverage, and technical indicators highlight significant risks. Investors should weigh these factors carefully.
To see Spark’s full report on ARAY stock, click here.
More about Accuray
Accuray Incorporated is a company dedicated to advancing radiation therapy, offering innovative solutions for complex and common cases in oncology and neuro-radiosurgery. Headquartered in Madison, Wisconsin, Accuray partners with clinicians and administrators worldwide to enhance patient care.
Average Trading Volume: 852,410
Technical Sentiment Signal: Sell
Current Market Cap: $166.7M
See more insights into ARAY stock on TipRanks’ Stock Analysis page.